JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence - Takeaways - MDSpire

JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence

  • By

  • Zhiying Wu

  • Li Jiang

  • Xu Zheng

  • Wanlin Zhou

  • Zuofeng Wang

  • Weilin Xie

  • July 1, 2026

  • 0 min

Share

  • 1

    JAK inhibitors are oral targeted synthetic DMARDs that may stabilize or improve lung function in RA-ILD without increasing ILD risk.

  • 2

    Preclinical studies indicate JAK inhibitors inhibit the IL-17A/JAK2/NF-κB axis, potentially offering anti-fibrotic effects in lung fibroblasts.

  • 3

    Clinical evidence shows JAK inhibitors have comparable efficacy to abatacept or rituximab in managing RA-ILD.

  • 4

    Real-world data suggest JAK inhibitors may pose higher mortality risks compared to TNF inhibitors, especially in older patients.

  • 5

    The use of JAK inhibitors in RA-ILD necessitates careful patient selection and risk-benefit assessment, pending further trials.

Original Source(s)

JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence

  • by Zhiying Wu, Li Jiang, Xu Zheng, Wanlin Zhou, Zuofeng Wang, Weilin Xie

  • July 1, 2026

Related Content

Gout May Signal Higher Stroke Risk in AF

In a nationwide Finnish cohort, patients with atrial fibrillation and gout had higher ischemic stroke rates, while urate-lowering therapy was associated with lower stroke rates.

Immunological coagulation dual axis stratification identifies ultra high-risk phenotypes in systemic sclerosis

Skin barrier dysfunction and correlation with the onset and progression of psoriasis